(Q34519220)

2 August 2017

1 reference

title

Neuraminidase inhibitors for the treatment and prevention of influenza (English)

1 reference

Jennifer McKimm-Breschkin

2 August 2017

author

series ordinal

0 references

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

103-112

1 reference

Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Low incidence of rimantadine resistance in field isolates of influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Characterization of the 1918 "Spanish" influenza virus neuraminidase gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

Position statement: global neuraminidase inhibitor susceptibility network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.103

21 January 2018

Identifiers

DOI

10.1517/14656566.3.2.103

1 reference

2 August 2017

1 reference